Elena L. Haarer

Elena L. Haarer

Auto-generated profile, based on publicly available information

Elena L. Haarer

Duke University School of Medicine 3 Medical Scientist Training Program Durham, North Carolina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
HUHannah J. Uckelmann
Hannah J. Uckelmann
EHElena L. Haarer
Elena L. Haarer
RTReina Takeda
Reina Takeda
EWEric M. Wong
Eric M. Wong
CHCharlie Hatton
Charlie Hatton
SAScott A. Armstrong
Scott A. Armstrong
The dysregulation of developmental and stem cell–associated genes is a common phenomenon during cancer development. Around half of patients with acute myeloid leukemia (AML) express high levels of HOXA cluster genes and MEIS1. Most of these AML cases harbor an NPM1 mutation (NPM1c), which encodes for an oncoprotein mislocalized from the nucleolus to the cytoplasm. How NPM1c expression in hematopoietic cells leads to its characteristic gene-expression pattern remains unclear. Here, we show that NPM1c directly binds to specific chromatin targets, which are co-occupied by the histone methyltransferase KMT2A (MLL1). Targeted degradation of NPM1c leads to a rapid decrease in gene expression and loss of RNA polymerase II, as well as activating histone modifications at its targets. We demonstrate that NPM1c directly regulates oncogenic gene expression in collaboration with the MLL1 complex and define the mechanism by which MLL1–Menin small-molecule inhibitors produce clinical responses in patients with NPM1-mutated AML. Significance: We uncovered an important functional role of mutant NPM1 as a crucial direct driver of oncogenic gene expression in AML. NPM1c can bind to chromatin and cooperate with the MLL complex, providing the first functional insight into the mechanism of Menin–MLL inhibition in NPM1c leukemias. See related article by Wang et al., p. 724. This article is highlighted in the In This Issue feature, p. 517

24 October 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
GBGaryk Brixi
Garyk Brixi
TYTianzheng Ye
Tianzheng Ye
LHLauren Hong
Lauren Hong
TWTian Wang
Tian Wang
CMConnor Monticello
Connor Monticello
PCPranam Chatterjee
Pranam Chatterjee
Protein-protein interactions (PPIs) are critical for biological processes and predicting the sites of these interactions is useful for both computational and experimental applications. We present a Structure-agnostic Language Transformer and Peptide Prioritization (SaLT&PepPr) pipeline to predict interaction interfaces from a protein sequence alone for the subsequent generation of peptidic binding motifs. Our model fine-tunes the ESM-2 protein language model (pLM) with a per-position prediction task to identify PPI sites using data from the PDB, and prioritizes motifs which are most likely to be involved within inter-chain binding. By only using amino acid sequence as input, our model is competitive with structural homology-based methods, but exhibits reduced performance compared with deep learning models that input both structural and sequence features. Inspired by our previous results using co-crystals to engineer target-binding “guide” peptides, we curate PPI databases to identify partners for subsequent peptide derivation. Fusing guide peptides to an E3 ubiquitin ligase domain, we demonstrate degradation of endogenous β-catenin, 4E-BP2, and TRIM8, and highlight the nanomolar binding affinity, low off-targeting propensity, and function-altering capability of our best-performing degraders in cancer cells. In total, our study suggests that prioritizing binders from natural interactions via pLMs can enable programmable protein targeting and modulation.

27 January 2023 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
EHElena L Haarer
Elena L Haarer
CTCorey J Theodore
Corey J Theodore
SGShirley Guo
Shirley Guo
RFRyan B Frier
Ryan B Frier
KCKenneth G Campellone
Kenneth G Campellone
The Arp2/3 complex is an actin nucleator with well-characterized activities in cell morphogenesis and movement, but its roles in nuclear processes are relatively understudied. We investigated how the Arp2/3 complex affects genomic integrity and cell cycle progression using mouse fibroblasts containing an inducible knockout (iKO) of the ArpC2 subunit. We show that permanent Arp2/3 complex ablation results in DNA damage, the formation of cytosolic micronuclei, and cellular senescence. Micronuclei arise in ArpC2 iKO cells due to chromatin segregation defects during mitosis and premature mitotic exits. Such phenotypes are explained by the presence of damaged DNA fragments that fail to attach to the mitotic spindle, abnormalities in actin assembly during metaphase, and asymmetric microtubule architecture during anaphase. In the nuclei of Arp2/3-depleted cells, the tumor suppressor p53 is activated and the cell cycle inhibitorCdkn1a/p21 mediates a G1 arrest. In the cytosol, micronuclei are recognized by the DNA sensor cGAS, which is important for stimulating a STING- and IRF3-associated interferon response. These studies establish functional requirements for the mammalian Arp2/3 complex in mitotic spindle organization and genome stability. They also expand our understanding of the mechanisms leading to senescence and suggest that cytoskeletal dysfunction is an underlying factor in biological aging.

2 January 2026 in Cancer Research
Verified
Journal Article
Closed access
BLBenjamin K. Lau
Benjamin K. Lau
EHElena L. Haarer
Elena L. Haarer
JAJeong Hyun Ahn
Jeong Hyun Ahn
Greg WangGreg Wang
Greg Wang
In cells, highly coordinated multivalent interactions give rise to discrete functional assemblies—commonly referred to as biomolecular condensates—that compartmentalize the molecular components required for specific biological reactions. These condensates are increasingly recognized as organizational entities with central roles in normal cellular regulation and in the pathogenesis of human cancers. In a recent issue of Cell, Datar and colleagues investigated the condensation of NPM1c, a common gene mutation in acute myeloid leukemias (AML). They demonstrated the necessity and sufficiency of NPM1c in forming nuclear condensates termed coordinating bodies (C-body), which show copartitioning of a suite of transcriptional coactivators such as NUP98, KMT2A/MLL1, menin, and XPO1/CRM1. While C-bodies are necessary for driving NPM1c-mutant AMLs, blockade of the copartitioned components within C-bodies, such as the XPO1/CRM1 or menin interaction by inhibitors, significantly alters the condensate composition and functionality. Likewise, a systematic deletion study of various regions within NPM1c pointed to a role for the coordinated multivalent interaction in establishing the functional condensates, as previously reported in studies of the Wilms tumor-causing ENL mutants and AML-causing NUP98 oncofusions. Comixing of C-bodies and condensates formed by the oncofusion of NUP98 or KMT2A/MLL1 in cells suggested they are biophysically indistinguishable, indicative of a shared pathogenic mechanism. Altogether, recent studies of multiple genetic drivers in human cancers have revealed a type of chromatin-bound multicomponent onco-condensate, which may motivate the development of onco-condensate disruptors that could potentially be used as broad treatments for cancer.

24 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
EHElena L. Haarer
Elena L. Haarer
SGShirley Guo
Shirley Guo
KCKenneth G. Campellone
Kenneth G. Campellone
The Arp2/3 complex is a ubiquitous actin nucleator with well-characterized activities in cell organization and movement, but its roles in chromatin-associated and cell cycle-related processes are relatively understudied. We investigated how the Arp2/3 complex affects genomic integrity, mitosis, and cell proliferation using mouse fibroblasts containing an inducible knockout (iKO) of the ArpC2 subunit. We show that permanent Arp2/3 ablation results in DNA damage, the formation of cytosolic micronuclei, and cellular senescence. Upon Arp2/3 depletion, cells undergo an abrupt proliferation arrest that is accompanied by activation of the tumor suppressor p53, upregulation of its downstream cell cycle inhibitor Cdkn1a /p21, and recognition of micronuclei by the cytosolic DNA sensor cGAS. Micronuclei arise in ArpC2 iKO cells due to chromosome segregation defects during mitosis and premature mitotic exits. Such phenotypes are explained by the presence of damaged chromatin fragments that fail to attach to the mitotic spindle, abnormalities in actin assembly during metaphase, and asymmetric microtubule architecture during anaphase. These studies establish functional requirements for the mammalian Arp2/3 complex in genome stability and mitotic spindle organization. They further expand our understanding of the intracellular mechanisms that lead to senescence and suggest that cytoskeletal dysfunction is an underlying factor in biological aging. Author Summary: The actin cytoskeleton consists of protein polymers that assemble and disassemble to control the organization, shape, and movement of cells. However, relatively little is understood about how the actin cytoskeleton affects genome maintenance, cell multiplication, and biological aging. In this study, we show that knocking out the Arp2/3 complex, a core component of the actin assembly machinery, causes DNA damage, genomic instability, defects in chromosome partitioning during mitosis, and a permanent cell proliferation arrest called senescence. Since senescent cells are major contributors to both age-associated diseases and tumor suppression, our findings open new avenues of investigation into how natural or experimental alterations of cytoskeletal proteins impact the process of aging and the regulation of cancer.

11 December 2025
Verified
Other
Open access
HUHannah J. Uckelmann
Hannah J. Uckelmann
EHElena L. Haarer
Elena L. Haarer
RTReina Takeda
Reina Takeda
EWEric M. Wong
Eric M. Wong
CHCharlie Hatton
Charlie Hatton
SAScott A. Armstrong
Scott A. Armstrong
Table S1. Read normalized ratios of ChIPseq signal of untreated versus dTAG-13 treated OCI-AML3-NPM1c-FKBP12 cells.Table S2. Summary of NPM1c and NPM1 Chromatin Binding Targets.Table S3. Patient info for patient derived xenograft (PDX) models used.Table S4. ChIPseq reads per kilobase (rpk) data summary of PDX samples with NPM1c-Ab and NPM1-Ab.Table S5. RNAseq differential expression data of OCI-AML3-NPM1c-FKBP12 treated with dTag-13 for 3 or 24 h and OCI-AML3 cells treated with Selinexor for 6 h.Table S6. SLAMseq differential expression data of OCI-AML3-NPM1c-FKBP12 cells treated with dTag-13 for 15, 30, 60, 120 or 180 minutes.Table S7. PROseq differentially transcribed genes in OCI-AML3-NPM1c-FKBP12 cells treated with dTag-13 for 30 or 60 minutes and OCI-AML3 cells treated with VTP-50469 for 48 hours.Table S8. CRISPR tiling screen with NPM1 WT specific guides (blue) and NPM1c specific guides (red).Table S9. ChIPseq rpk values for CRM1 and HA ChIPs in 293T cells.Table S10. RNAseq differential gene expression analysis in 293T cells after overexpression of NPM1c-HA compared to all other samples (MIG, NPM1wt-HA and AS1-HA).Table S11. Fold change in ChIPseq differential peak interval signal in OCI-AML3 cells treated with Selinexor (100 nM, 6 hours) or VTP-50469 (330 nM, 96 hours).Table S12. Oligos used in this study.Table S13. Antibodies used in this study.Table S14. Summary of total and mapped reads of ChIPseq samples.